Experience effective symptom management for interstitial cystitis with Cryoserv Injection (Dimethyl Sulfoxide) 50 mL, enhancing bladder health and comfort.
Cystitis is inflammation of the bladder, usually caused by a bladder infection. It's a common type of urinary tract infection (UTI), particularly in women, and is usually more of a nuisance than a cause for serious concern. Mild cases will often get better by themselves within a few days.
Dimethyl Sulfoxide injection is a sterile solution containing 50% dimethyl sulfoxide (DMSO) and 50% distilled water. DMSO is a colorless liquid that is used medically as an anti-inflammatory and diuretic agent. It can also increase the body's absorption of other medications when applied topically or injected. It is commonly used to treat bladder inflammation, interstitial cystitis, and certain skin conditions. This injection form is typically used in hospital settings for quick and efficient administration of the medication.
Cryoserv Injection Dimethyl Sulfoxide Bladder inflammation Treatment 50 mL is a highly effective and recommended treatment option for individuals suffering from bladder inflammation. This advanced medical solution is specifically designed to alleviate the symptoms of bladder inflammation, such as pain, discomfort, and frequent urination. Cryoserv Injection contains Dimethyl Sulfoxide, a powerful anti-inflammatory agent that works by reducing the swelling and inflammation in the bladder. This treatment is available in a convenient 50 mL vial, making it easy to administer and store. The benefits of Cryoserv Injection include fast and long-lasting relief from bladder inflammation, minimal side effects, and a high success rate. This treatment is highly recommended by medical professionals for its effectiveness and safety in managing bladder inflammation. With Cryoserv Injection, individuals can experience an improved quality of life, free from the discomfort and inconvenience of bladder inflammation.
NDC: 67457-0178-50
UPC: 367457-178509
Size: 50 mL
Manufacture: Mylan Institutional
Skip to content
